<p>Vinegar-baked Radix Bupleuri (VBRB) prescriptions have been used to treat chronic hepatitis B in clinic and achieved good efficacy. Polysaccharides are the main active ingredients of VBRB, but their anti-HBV activity remains unclear. This study aimed to explore the anti-HBV activity of a VBRB polysaccharide in the HepG2.2. 15 cell line and its underlying mechanism. The VBRB polysaccharide (VBCP-2) was separated and purified using various chromatographic methods. Its structure was investigated by chemical and spectroscopic analyses. Anti-HBV activity was evaluated by determining the levels of HBsAg and HBeAg in supernatants after co-culturing VBCP-2 with HepG2.2.15 cells. Gene expressions of encoding DNA polymerase (HBV-P), HBV-C, HBV-S, HBx, HNF1α and HNF-4α were determined by RT-PCR, while the protein expression of HNF-4α, HNF-1α, ERK/p38 MAPK and TLR4/MyD88/NF-κB were evaluated by western blotting to explore the mechanism. The results showed that VBCP-2 was a heteropolysaccharide with an average molecular weight of 2195.8&#xa0;kDa, its structure was characterized. VBCP-2 significantly inhibited the content of HBsAg and HBeAg, and all four open reading frames of HBV DNA replication. It decreased the expressions of HNF-4α and HNF-1α, as well as the protein expressions of p-ERK1/2 and p-p38MAPK, but a marginal effect was observed on the protein expressions of TLR4, MyD88, kappa B inhibitor alpha (IκBα) and phosphorylated (p)-NF-κB p65. VBCP-2 exerts anti-HBV effects by decreasing HNF-4α and HNF-1α expressions and regulating the immune system through down-regulating p38 MAPK and p-ERK1/2 proteins, making it a promising candidate for anti-HBV infection.</p>

错误:搜索内容不能为空,请输入英文关键词
错误:关键词超出字数限制,请精简
高级检索

Anti-Hepatitis B Virus Activities of a Polysaccharide from Vinegar-Baked Radix Bupleuri in Vitro: Evidences for its Mechanisms of Action

  • Ya Zhao,
  • Xiao Zhang,
  • Peng Wan,
  • Yayun Wu,
  • Xiaoshuang Wang,
  • Lijuan Liu,
  • Qiaohong Hu,
  • Shirui Mao,
  • Ruizhi Zhao

摘要

Vinegar-baked Radix Bupleuri (VBRB) prescriptions have been used to treat chronic hepatitis B in clinic and achieved good efficacy. Polysaccharides are the main active ingredients of VBRB, but their anti-HBV activity remains unclear. This study aimed to explore the anti-HBV activity of a VBRB polysaccharide in the HepG2.2. 15 cell line and its underlying mechanism. The VBRB polysaccharide (VBCP-2) was separated and purified using various chromatographic methods. Its structure was investigated by chemical and spectroscopic analyses. Anti-HBV activity was evaluated by determining the levels of HBsAg and HBeAg in supernatants after co-culturing VBCP-2 with HepG2.2.15 cells. Gene expressions of encoding DNA polymerase (HBV-P), HBV-C, HBV-S, HBx, HNF1α and HNF-4α were determined by RT-PCR, while the protein expression of HNF-4α, HNF-1α, ERK/p38 MAPK and TLR4/MyD88/NF-κB were evaluated by western blotting to explore the mechanism. The results showed that VBCP-2 was a heteropolysaccharide with an average molecular weight of 2195.8 kDa, its structure was characterized. VBCP-2 significantly inhibited the content of HBsAg and HBeAg, and all four open reading frames of HBV DNA replication. It decreased the expressions of HNF-4α and HNF-1α, as well as the protein expressions of p-ERK1/2 and p-p38MAPK, but a marginal effect was observed on the protein expressions of TLR4, MyD88, kappa B inhibitor alpha (IκBα) and phosphorylated (p)-NF-κB p65. VBCP-2 exerts anti-HBV effects by decreasing HNF-4α and HNF-1α expressions and regulating the immune system through down-regulating p38 MAPK and p-ERK1/2 proteins, making it a promising candidate for anti-HBV infection.